|
Symbol
|
AWSBIL | ZYALTQ | SKS4LK | OVCRCH | OZTRCH | Z0A4JZ | AANOTQ | ABVHSQ | AYSBIL | LXORLK | Z0ATYZ | CQWBKB | ACDQTQ | RMAKRV | RMAG0V | Z0B7EZ | UJERWU | LZPRCH | RMBGJV | RMBU5V |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nom | Multi Reverse Convertible | Multi Reverse Convertible | LUKB Softcallable Multi Reverse Convertible | Worst of Callable Reverse Convertible | Worst of Callable Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Multi Reverse Convertible | Multi Reverse Convertible | Reverse Convertible | LUKB Multi Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Reverse Convertible | Multi Reverse Convertible | Autocallable Multi Vonti | Autocallable Multi Vonti | Autocallable Reverse Convertible Defensive worst | GOAL | Worst of Callable Reverse Convertible | Multi Vonti | Multi Vonti |
|
Sous-jacent
|
Compagnie Financière Richemont SA / Logitech International SA / Sika AG / Straumann Hldg. AG | Givaudan / Sonova Hldg. AG / Straumann Hldg. AG | Julius Baer Group / Roche AG / Straumann Hldg. AG | Novartis AG / Sandoz Group AG / Straumann Hldg. AG | Kühne & Nagel Intl. AG / Straumann Hldg. AG / VAT Group | ABB / Holcim/Amrize Basket / Straumann Hldg. AG | Adecco Group AG / OC Oerlikon N / Straumann Hldg. AG / VAT Group | Sika AG / Helvetia Baloise Holding AG / Straumann Hldg. AG / Sandoz Group AG | Alcon / Sonova Hldg. AG / Straumann Hldg. AG / Ypsomed Hldg. AG | Givaudan / Julius Baer Group / Straumann Hldg. AG | Alcon / Novartis AG / Sandoz Group AG / Straumann Hldg. AG | Lonza Group N / Novartis N / Roche GS / Straumann Hldg. AG | Adecco Group AG / Logitech International SA / Stadler Rail AG / Straumann Hldg. AG / UBS Group AG | Lonza Group N / Sika AG / Straumann Hldg. AG | Lonza Group N / Sika AG / Straumann Hldg. AG | Alcon / Straumann Hldg. AG / Ypsomed Hldg. AG | Bachem Hldg. AG / Lonza Group N / Straumann Hldg. AG | SGS S.A. Ltd. / Sika AG / Straumann Hldg. AG | Alcon / Lonza Group N / Novartis AG / Straumann Hldg. AG | Lonza Group N / Novartis AG / Straumann Hldg. AG / Ypsomed Hldg. AG |
|
Emetteur
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Échéance
|
23.10.2026 | 02.11.2026 | 10.07.2026 | 09.06.2026 | 07.04.2026 | 30.03.2026 | 27.09.2029 | 07.10.2026 | 22.04.2027 | 05.03.2027 | 05.03.2027 | 13.03.2028 | 21.03.2030 | 24.06.2026 | 24.06.2026 | 10.12.2026 | 02.08.2027 | 07.08.2029 | 19.08.2027 | 22.02.2027 |
| Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Prix d'exercise
|
135,512 | 95,289 | 39,21 | 94,0875 | 97,23 | 100,793 | 81,12 | 183,04 | 224,70 | 2 812,194 | 66,1674 | 78,705 | 18,434 | 183,40 | 174,30 | 317,85 | 75,3422 | 150,75 | 75,92 | 292,70 |
| rendement max. p.a. | 9,57% | - | 10,81% | 20,76% | - | 73,67% | 12,96% | - | 24,71% | 13,17% | 20,28% | 7,54% | 11,42% | 57,09% | 42,33% | 23,28% | 10,17% | 8,35% | 8,70% | 13,35% |
| Demande | 97,34 | 90,01 | - | 95,81 | 94,99 | - | 78,69 | 84,92 | 82,50 | - | - | 95,43 | 80,95 | 85,80 | 89,60 | - | - | 90,67 | 94,80 | 91,20 |
| Offre | 98,14 | - | - | 96,61 | - | - | 79,48 | - | 83,30 | - | - | 96,23 | 81,75 | 86,60 | 90,40 | - | - | 91,47 | 95,80 | 92,20 |